Revolutionizing Chimerism Monitoring

The latest innovation in chimerism testing offers streamlined workflow with best-in-class sensitivity.

Chimerism changes after hematopoietic cell transplant can be an early indication of relapse.*

Key Features

• A NGS based chimerism testing solution that is able to determine the relative contribution of up to 3 genomes in a single sample i.e. up to two donors per recipient 

• A kit based test that offers high quality data with a recommended input of 10 ng of gDNA and up to 96 samples per batch 

• One-step multiplex assay that utilizes 202 SNPs across all autosomal chromosomes to differentiate between recipient and donor(s) gDNA 

• A highly sensitive, scalable assay with time-saving automated analysis software

*AlloSeq HCT is available as CE/IVD and Research Use Only. For local regulatory status, please contact CareDx. Research Use Only products are not to be used for diagnostic procedures. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office.